Company intelligence / Profile preview
Celixir
Stratford-upon Avon/Cardiff, England/Wales, United Kingdomcelixir.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Celixir developed a proprietary allogeneic cell therapy platform focused on heart failure. Its lead product, Heartcel™ (immunomodulatory progenitor cells), was tested in a Phase 1/2 trial for ischemic cardiomyopathy with initial safety and feasibility demonstrated. Clinical progress was delayed by the COVID pandemic but is being revived following acquisition by Ashington Innovation via SPAC reverse merger in 2023. Patents have been granted for their technology in the US, EU, and Asia.
- Therapeutic areas
- Cardiovascular
- Modalities
- Cell therapyAllogeneic cell therapyImmunomodulatory progenitor cells (iMPs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Celixir.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celixir.